Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SUTRO BIOPHARMA, INC.

Get SEC filing alerts via email and in your feed for SUTRO BIOPHARMA, INC.

STRO

SUTRO BIOPHARMA, INC.

About SUTRO BIOPHARMA, INC.

Sutro Biopharma is an oncology-focused biopharmaceutical company developing site-specific antibody drug conjugates (ADCs) and next-generation protein therapeutics using its proprietary cell-free XpressCF platform. Its core activities include designing targeted cancer therapies, advancing clinical and preclinical ADC candidates, and forming strategic collaborations with leading pharma companies. The company aims to create safer, more effective biologics for unmet cancer treatment needs through innovative protein synthesis and conjugation technologies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from SUTRO BIOPHARMA, INC.

1
1
SUTRO BIOPHARMA, INC. Sutro Biopharma Reports $38.5 Million Net Loss in Q1 2026, Revenue Declines 17%

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
SUTRO BIOPHARMA, INC. Sutro Biopharma Reports $191.1 Million Net Loss and $102.5 Million Revenue for 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
SUTRO BIOPHARMA, INC. Sutro Biopharma Reports 14% Revenue Growth in Q3 2025, Net Loss Increases to $56.9 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
SUTRO BIOPHARMA, INC. Sutro Biopharma Reports 148% Revenue Growth, Net Loss Improvement in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
SUTRO BIOPHARMA, INC. Sutro Biopharma Reports $75.97 Million Net Loss and $17.40 Million Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
SUTRO BIOPHARMA, INC. Sutro Biopharma Reports $227.4 Million Net Loss for 2024, Revenue Decrease of 60%

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
SUTRO BIOPHARMA, INC. Sutro Biopharma Reports 50% Revenue Decline, Increased Operating Expenses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments